Navigation Links
Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA
Date:10/15/2008

SUNNYVALE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the U.S. Food & Drug Administration (FDA) categorized Cepheid's Xpert(TM) MRSA/SA Skin and Soft Tissue Infection (SSTI) test as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments (CLIA). The new test is designed for on-demand detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), (typically Methicillin-sensitive) in SSTIs. Xpert MRSA/SA SSTI runs on Cepheid's GeneXpert(R) System, the leading platform for on-demand detection of Healthcare Acquired Infections (HAIs).

Cleared by the FDA for marketing last month, Xpert MRSA/SA SSTI is the first molecular SSTI diagnostic test to receive the moderate complexity CLIA categorization. With this designation, the test is available for use inside and outside of the traditional laboratory setting in approximately 6,000 hospitals throughout the U.S.

"The value proposition of Xpert MRSA/SA SSTI is resonating well with physicians and surgeons -- the healthcare professionals who order tests and prescribe antibiotics as a part of patient treatment plans," said Cepheid Chief Executive Officer John Bishop. "With 'Moderate Complexity' categorization, SSTI test results can be obtained in emergency departments or other near-patient settings in addition to the central laboratory. The key benefit is a potential further reduction in the test time-to-result thereby improving patient management decisions."

MRSA is a bacterium that has become resistant to multiple antibiotics including penicillin and cephalosporins. Current culture-based lab testing methods require 24 - 72 hours to determine if a skin or soft tissue infection is caused by MRSA or SA. As a result, physicians and surgeons often prescribe broad-spectrum, but often suboptimal, antimicrobial therapies while awaiting specific culture and susceptibility results.

In less than one hour, Cepheid's X
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
2. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
3. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
4. Cepheid to Webcast Upcoming Financial Presentations
5. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
6. Cepheid Reports Second Quarter Revenue of $42.1 Million
7. Cepheid to Webcast Analyst Event
8. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
9. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
10. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
11. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/1/2014)... 2014 Reportlinker.com announces that a new ... India Solid Waste Management Vehicles Market ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In India ... bodies responsible for complete handling and regulation of ... around 135,000 MT solid waste is generated daily ...
(Date:8/31/2014)... Available spectra is similar for all L-series ... of a wide range of plants. The spectra ... patented and pending wide spectrum technology. The single ... applications in contrast to growth spectra made from ... a large variety of differently sized and shaped ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Identify Potential Initiation Dosing Regimen , ... palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant ... of a 13-week study presented today (1). Statistical ... and 150 mg equivalent [eq.a]), when given every 4 ...
... the Journal Blood for the American Society of Hematology Annual ... Dec. 10 Alfacell Corporation (Nasdaq: ACEL ) ... abstracts in Blood (2008 112: Abstract 4205 & ... (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and ...
... Calif., Dec. 10 Valeant,Pharmaceuticals International (NYSE: ... signed a,definitive agreement to acquire Dow Pharmaceutical Sciences, ... the development of topical,products on a proprietary basis, ... The transaction significantly enhances Valeant,s,dermatology franchise in the ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5
(Date:9/2/2014)... Passerine birds, also known as perching birds, that migrate ... they do in autumn to reach their destinations. This ... birds that only make short migratory flights, says researcher ... journal Behavioral Ecology and Sociobiology . , ... used a tracking radar to measure over three years ...
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... speech President Bush said technology is the best way to ... Energy Joint Genome Institute (DOE JGI) is directing the technology ... will lead to cheaper and easier to produce biofuels. ... molecular biology we can generate diagnostic fingerprints, Environmental Genomic Tags ...
... the March 24 Cell reports the discovery of a ... could offer a potential new target for countermeasures against ... therapies might have the potential to protect against anthrax ... have lost their therapeutic value, they added. , The ...
... Scientists have for many years debated the cause of ... Papagrigorakis and colleagues using DNA collected from teeth from ... as the disease responsible for this devastating epidemic. The ... Journal of Infectious Diseases (IJID) published by Elsevier on ...
Cached Biology News:Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2Driver of anthrax toxicity could lead to late-stage therapy 2Typhoid fever led to the fall of Athens 2
... Reagents are complete ready-to-use reagents for the ... is specifically formulated for the isolation of ... is specifically formulated for the isolation of ... with DNAzol Reagents can be used for ...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: